SCOPUS 정보 검색 플랫폼

Cancer Biology and Therapy

Volumn 17, Issue 2, 2016, Pages 123-124

The promising role of nivolumab in renal cell cancers

(4) Gupta, Kanika a Tiu, Dorenett Yu a Tiu, John a Aragon Ching, Jeanny B b

a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES (United States)

b Inova Dwight and Martha Schar Cancer Institute (United States)

Author keywords

Immune checkpoint inhibitors; metastatic kidney cancers; nivolumab

Indexed keywords

ANGIOGENESIS INHIBITOR; EVEROLIMUS; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; HUMAN; INTESTINE ISCHEMIA; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; NAUSEA; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; STOMATITIS; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; EVEROLIMUS; HUMANS; IMMUNOGLOBULIN G; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84961214331 PISSN: 15384047 EISSN: 15558576 Source Type: Journal
DOI: 10.1080/15384047.2016.1139269 Document Type: Article

Times cited : (7)

References (4)

1
- 84920837701
- Cancer statistics, 2015
- 25559415
- R.L.Siegel, K.D.Miller, A.Jemal. Cancer statistics, 2015. CA: A Cancer J Clin 2015; 65: 5-29. PMID: 25559415; http://dx.doi.org/10.3322/caac.21254
- (2015) CA: A Cancer J Clin , vol.65 , pp. 5-29
- Siegel, R.L.¹ Miller, K.D.² Jemal, A.³

2
- 0028266553
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
- 8120958
- S.A.Rosenberg, J.C.Yang, S.L.Topalian, D.J.Schwartzentruber, J.S.Weber, D.R.Parkinson, C.A.Seipp, J.H.Einhorn, D.E.White. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271(12):907-13. PMID: 8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
- (1994) JAMA , vol.271 , Issue.12 , pp. 907-913
- Rosenberg, S.A.¹ Yang, J.C.² Topalian, S.L.³ Schwartzentruber, D.J.⁴ Weber, J.S.⁵ Parkinson, D.R.⁶ Seipp, C.A.⁷ Einhorn, J.H.⁸ White, D.E.⁹

3
- 33645736792
- Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
- 16585157
- R.H.Thompson, S.M.Kuntz, B.C.Leibovich, H.Dong, C.M.Lohse, W.S.Webster, S.Sengupta, I.Frank, A.S.Parker, H.Zincke, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66(7):3381-5. PMID: 16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
- (2006) Cancer Res , vol.66 , Issue.7 , pp. 3381-3385
- Thompson, R.H.¹ Kuntz, S.M.² Leibovich, B.C.³ Dong, H.⁴ Lohse, C.M.⁵ Webster, W.S.⁶ Sengupta, S.⁷ Frank, I.⁸ Parker, A.S.⁹ Zincke, H.¹⁰

4
- 84946607195
- CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma
- 26406148
- R.J.Motzer, B.Escudier, D.F.McDermott, S.George, H.J.Hammers, S.Srinivas, S.S.Tykodi, J.A.Sosman, G.Procopio, E.R.Plimack, et al. CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19):1803-13. PMID: 26406148; http://dx.doi.org/10.1056/NEJMoa1510665
- (2015) N Engl J Med , vol.373 , Issue.19 , pp. 1803-1813
- Motzer, R.J.¹ Escudier, B.² McDermott, D.F.³ George, S.⁴ Hammers, H.J.⁵ Srinivas, S.⁶ Tykodi, S.S.⁷ Sosman, J.A.⁸ Procopio, G.⁹ Plimack, E.R.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.